Director Jesse G. Singh filed a Form 4 with the SEC on November 13, 2026, reporting the sale of 25,000 ordinary shares of James Hardie Industries plc on November 11, 2026.
Meritage Homes Corporation Chief Executive Officer and Director Phillippe Lord filed a Form 4 with the SEC on November 13, 2026, disclosing a charitable gift of 7,100 shares of MTH Common Stock transacted on November 10, 2026.
Markus Puhlmann, Chief Medical Officer of Perspective Therapeutics, Inc., filed a Form 4 on November 13, 2026, disclosing open-market purchases of 41,000 shares of common stock across two transactions on November 11 and November 12, 2026.
Medalist Diversified, Inc. filed its quarterly report on Form 10-Q with the SEC on November 13, 2026, covering the three and nine months ended September 30, 2026, disclosing significant gains from property disposals and a major shift in its balance sheet composition.
Katapult Holdings, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026 with the U.S. Securities and Exchange Commission on November 13, 2026, covering both third-quarter and nine-month results following a significant merger transaction completed during the period.
Soren Acquisition Corp. filed its Form 10-Q for the quarter ended September 30, 2026 with the Securities and Exchange Commission on November 13, 2026, reporting financial results for the three and nine months ended September 30, 2026.
Indaptus Therapeutics, Inc. filed its quarterly report on Form 10-Q for the period ended September 30, 2026, with the SEC on November 13, 2026, disclosing a significant increase in cash and a sharply reduced operating loss compared to the prior year period.
Cineverse Corp. filed its quarterly report on Form 10-Q with the SEC on November 13, 2026, covering the fiscal quarter and six months ended September 30, 2026.
FRP Holdings, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026 with the U.S. Securities and Exchange Commission, reporting a net loss attributable to the company of $165 thousand for the third quarter.
TuHURA Biosciences, Inc. reported financial results for the third quarter ended September 30, 2026, disclosing cash of $1.9 million, key clinical and regulatory updates, and two new U.S. patents, in a press release filed November 13, 2026.